Apimeds Pharmaceuticals Financials - Benzinga

SPY765.40 QQQ737.32+0.11%BTC/USD84,005.80+0.66%DIA513.76−0.05%GLD380.24+0.62%TLT78.620.00%

Apimeds Pharmaceuticals Us Inc

APUSAMEX

Trade with Public

Trade with Public

$6.39

-0.86-11.86%

At close: Sep 28, 5:00 PM EST

Overview News Earnings ForecastFinancialsSentiment Ownership Compare Stock Report

Apimeds Pharmaceuticals Financials

Apimeds Pharmaceuticals (APUS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Apimeds Pharmaceuticals Q1 EPS $(2.26) Down From $(0.50) YoY

Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(2.26) per share. This is a 352 percent decrease over losses of $(0.50) per share from the same period last year.

Benzinga Newsdesk

PRO
Apimeds Pharmaceuticals Q4 EPS $(0.80) Down From $(0.50) YoY

Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(0.80) per share. This is a 60 percent decrease over losses of $(0.50) per share from the same period last year.

Benzinga Newsdesk

PRO
Apimeds Pharmaceuticals Q2 EPS $(0.26) Down From $(0.06) YoY

Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(0.26) per share. This is a 333.33 percent decrease over losses of $(0.06) per share from the same period last year.

Benzinga Newsdesk